Skip Navigation


Annals of Oncology Advance Access originally published online on May 9, 2006
Annals of Oncology 2006 17(7):1166-1171; doi:10.1093/annonc/mdl087
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/7/1166    most recent
mdl087v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Safarinejad, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Safarinejad, M. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Iran

M. R. Safarinejad

Urology Nephrology Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran

Correspondence to: Dr M. R. Safarinejad, P.O. Box 19395–1849, Tehran, Iran. Tel: +98 21 22454499; Fax: +98 21 22456845; E-mail: safarinejad{at}unrc.ir

Purpose: To evaluate the natural background of prostate cancer in Iran a large population-based study of screening using total prostate-specific antigen (tPSA) and per cent free PSA (fPSA) as the initial test was performed.

Materials and methods: For 9 years (1996 to 2004) in Tehran, Iran, 3670 Iranian men older than 40 years were mass checked by PSA-based screening. They were invited to have a digital rectal examination (DRE), serum PSA assay and transrectal ultrasonography (TRUS)-guided sextant prostate biopsy to see if the DRE was clinically suspicious of malignancy, the serum PSA was ≥2.1 ng/ml or free-to-total PSA (f/tPSA) ratio ≤15%.

Results: In 433 (11.8%) of screened males, tPSA levels exceeded the cut-off value of ≥2.1 ng/ml and 128 prostate cancers were diagnosed [positive predictive value (PPV) 29.6%] corresponding to an overall detection rate of 3.5%. Altogether 138 cancers were detected (detection rate 3.8%); none were stage M1, three were stage N+ and 4 stage T3. A threshold tPSA of ≥2.1 ng/ml would have detected 128 cancers in 447 biopsied men (PPV 29%). There were 109 of 138 (79%) men with cancer who had an f/tPSA of ≤15%, while 152 of 305 (49.8%) with benign biopsies had a f/tPSA of ≤15%, which corresponds to a PPV of 30.8%.

Conclusion: PSA-based screening with low PSA cut-off values increase the detection rate of clinically significant, organ confined and potentially curable prostate cancer. Further studies are warranted in order to determine the incidence and prevalence of prostate cancer in different ethnic groups.

Key words: prostate cancer, epidemiology, prostatic specific antigen, screening


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.